Delivery Order SPE2DB22D3301-SPE2DB26FX4PX
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $14,597.62 to AmerisourceBergen Drug Corp for the supply of Pomalyst 4 mg capsules (21-count units) on November 13, 2025, with an ultimate completion date of December 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of Pomalyst 1 mg capsules (100-count units) with a ceiling value of $292,457.73. This firm fixed price delivery order, with an ultimate completion date of May 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was...
- The Defense Logistics Agency awarded a delivery order valued at $27,703.52 to AmerisourceBergen Drug Corp on September 28, 2025, for the supply of Pomalyst (pomalidomide) 4 mg capsules in a 21-count package. This is a firm fixed-price, competitively awarded contract with an ultimate completion date of October 20, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 20, 2025, for the supply of Pomalyst (pomalidomide) 1 mg capsules in quantities of 100 units. This firm fixed price delivery order, valued at $114,147.61, is set to be completed by July 14, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation, reflecting the company's demonstrated...
- The Defense Logistics Agency awarded a delivery order valued at $70,259.33 to AmerisourceBergen Drug Corp for the supply of Pomalyst 1 mg capsules (100-count units). This firm fixed-price delivery order, issued on August 29, 2025, represents a non-competitive, non-set-aside procurement and is scheduled for completion by September 22, 2025. The award will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Pomalyst (pomalidomide) is an immunomodulatory...
- This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,236.98 fixed-price delivery order contract is for the supply of POMALYST 3 MG CAPSULE 21S, a specialty medication. The contract has an ultimate completion date of May 11, 2023 and was awarded on April 20, 2023. This contract is not designated as a set-aside and is part of a larger $999,999,999 Indefinite...
- This federal contract award, valued at $23,971.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the supply of POMALYST 2 MG CAPSULE 21S, a specialty pharmaceutical product, with a period of performance through February 20, 2025. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a delivery order worth $22,938.76 to provide 4564977355 POMALYST 2 MG CAPSULE 21S to the Defense Logistics Agency (DLA). The award is not set aside and is a firm fixed-price contract with a completion date of July 15, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999.00 through December 31, 2025, which serves as the primary...
- The Defense Logistics Agency awarded a $20,286 delivery order to AmerisourceBergen Drug Corp for Pemazyre 13.5 mg tablets (quantity 14) under a firm fixed-price contract. The award, issued on September 25, 2025, has an ultimate completion date of October 17, 2025, and represents a non-set-aside competitive award. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania will serve as the place of performance. This delivery order is a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Paxlovid 300-100 mg dose packs in quantities of 30 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $20,945.82 and is scheduled for completion by September 9, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB26FX4PXDelivery Order
The Defense Logistics Agency awarded a $13,851.76 delivery order to AmerisourceBergen Drug Corp for Pomalyst 4 mg capsules (21-count) on November 12, 2025, with completion targeted for December 4, 2025. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made on a competitive, non-set-aside basis, and performance will occur at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across the Department of Defense healthcare systems. The company's comprehensive portfolio includes brand-name and generic medications, vaccines, and specialized medical supplies supporting military healthcare programs worldwide. This award for Pomalyst, a specialty pharmaceutical used in oncology treatment, exemplifies the contractor's extensive role in supplying specialized medications through the DLA's medical supply chain network serving the Defense Health Agency, U.S. Coast Guard, and other federal healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.9k | 11/12/25 |